You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle
SBC: CytoInformatics LLC Topic: NIADESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Antibody targeting of ADAM for treatment of triple negative breast cancer
SBC: ADECTO PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes
SBC: BIONIKS Topic: NIAMSDESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
T SS needle protein inhibitors for the treatment of P aeruginosa infection
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Intervention to encourage HIV Testing and Counseling among Adolescents
SBC: Schell Games LLC Topic: NICHDDESCRIPTION provided by applicant HIV disproportionately impacts minority adolescents and most of them have neither undergone HIV testing and counseling HTC nor know their status Adolescence is a andquot window of opportunityandquot to intervene with HIV behavior change interventions Challenges to implementing and disseminating some effective HIV prevention programs in adolescents may lim ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients
SBC: CAPRICOR, INC. Topic: NHLBIDESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NHLBIDESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
New piperazines effecting Abeta oligomer displacement from neuronal receptors
SBC: COGNITION THERAPEUTICS, INC. Topic: NIADESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease Recent scientific discoveries have identified oligomers of the brain protein Abeta as toxic culprits in the disease process Cognition has discovered therapeutic molecules that displace Abeta oligomers from neurons and block the downstream pathol ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide inhibitors for neuroinflammation and neurodegeneration
SBC: PROVAIDYA Topic: NIADESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health